ZBIO

Zenas BioPharma, Inc. NASDAQ Listed Sep 13, 2024

Healthcare ·Biotechnology ·US · zenasbio.com

$19.19

Mkt Cap $856.7M

52w Low $8.54 29.5% of range 52w High $44.60

50d MA $21.99 200d MA $24.32

P/E (TTM) -2.3x

EV/EBITDA -7.5x

P/B 3.6x

Debt/Equity 0.3x

ROE -156.0%

P/FCF -9.4x

RSI (14) —

ATR (14) —

Beta -0.51

50d MA $21.99

200d MA $24.32

Avg Volume 771.8K

Zenas BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of transformative immunology-based therapies. Its lead product candidate is obexelimab, a bifunctional monoclonal antibody for various indications, including immunoglobulin G4-related disease, multiple sclerosis, systemic lupus erythematosus, and warm autoimmune hemolytic anemia. The company also develops ZB002, an anti-TNFa monoclonal antibody; ZB004, a cytotoxic T-lymphocyte-associated antigen 4-immunoglobulin fusion; ZB001, an anti-insulin-like growth factor-1 receptor monoclonal antibody; and ZB005, an anti-active complement component 1s monoclonal antibody. Zenas BioPharma, Inc. was formerly known as Zenas BioPharma (Cayman) Limited and changed its name to Zenas BioPharma, Inc. in August 2023. The company was incorporated in 2019 and is based in Waltham, Massachusetts.

SIC Code

2834

CIK (SEC)

1953926

Phone

(857) 271-2954

North Building · Waltham, MA 02451 · US

Date	Time	Est	Rptd	Surp	Base	Gap%	D1%	D2%	D3%	D4%	D5%	Guide ▲★
Mar 16, 2026	AMC	-1.00	-1.10	-9.8%	23.23	+1.0%	+1.1%	-1.9%	+1.5%	-4.6%	-7.5%	—
Nov 12, 2025	AMC	-0.87	-1.22	-40.2%	35.80	-1.6%	-0.4%	-1.9%	+2.5%	+0.9%	+2.6%	—
Aug 12, 2025	AMC	-1.02	-1.25	-22.5%	15.90	+1.9%	+5.1%	+0.3%	+0.4%	+2.7%	-8.3%	—
May 15, 2025	AMC	-1.11	-0.80	+27.9%	9.74	+0.1%	+7.5%	+5.2%	+4.3%	-4.7%	+4.7%	—
Mar 25, 2025	AMC	-0.92	-3.99	-333.7%	9.11	-0.9%	-11.5%	-0.4%	+1.7%	-3.3%	-3.8%	—
Nov 12, 2024	AMC	-9.33	-5.02	+46.2%	20.61	+0.0%	-7.3%	-1.9%	-8.6%	-11.8%	-3.9%	—
Jun 30, 2024	AMC	—	-0.99	—	—	—	—	—	—	—	—	—
Mar 31, 2024	AMC	—	-0.73	—	—	—	—	—	—	—	—	—
Dec 31, 2023	AMC	—	-0.64	—	—	—	—	—	—	—	—	—
Sep 30, 2023	AMC	—	0.85	—	—	—	—	—	—	—	—	—
Jun 30, 2023	AMC	—	-0.76	—	—	—	—	—	—	—	—	—
Mar 31, 2023	AMC	—	-0.50	—	—	—	—	—	—	—	—	—

Date	Firm	Action	Grade	Target	Base	Open	Gap%	D1%	D2%	D3%	D4%	D5%
Mar 17	Citigroup	Maintains	Buy → Buy	—	$23.23	$23.46	+1.0%	+1.1%	-1.9%	+1.5%	-4.6%	-7.5%
Mar 17	Morgan Stanley	Maintains	Equal Weight → Equal Weight	—	$23.23	$23.46	+1.0%	+1.1%	-1.9%	+1.5%	-4.6%	-7.5%
Mar 17	Guggenheim	Maintains	Buy → Buy	—	$23.23	$23.46	+1.0%	+1.1%	-1.9%	+1.5%	-4.6%	-7.5%
Mar 17	HC Wainwright & Co.	Maintains	Buy → Buy	—	$23.23	$23.46	+1.0%	+1.1%	-1.9%	+1.5%	-4.6%	-7.5%
Feb 10	HC Wainwright & Co.	Maintains	Buy → Buy	—	$22.48	$22.48	+0.0%	-4.4%	+8.3%	+12.2%	+1.1%	+1.4%
Jan 6	Morgan Stanley	Downgrade	Overweight → Equal Weight	—	$16.61	$15.75	-5.2%	-8.5%	+8.6%	-0.6%	-2.0%	+23.0%
Dec 22	Wedbush	Maintains	Outperform → Outperform	—	$36.15	$36.16	+0.0%	+17.1%	+1.1%	+0.8%	-1.6%	-8.1%
Nov 13	Morgan Stanley	Maintains	Overweight → Overweight	—	$35.80	$35.22	-1.6%	-0.4%	-1.9%	+2.5%	+0.9%	+2.6%
Oct 28	HC Wainwright & Co.	Maintains	Buy → Buy	—	$31.80	$32.00	+0.6%	-5.1%	-7.2%	+6.7%	+4.6%	+0.3%
Oct 28	Citigroup	Maintains	Buy → Buy	—	$31.80	$32.00	+0.6%	-5.1%	-7.2%	+6.7%	+4.6%	+0.3%
Oct 28	Morgan Stanley	Maintains	Overweight → Overweight	—	$31.80	$32.00	+0.6%	-5.1%	-7.2%	+6.7%	+4.6%	+0.3%
Oct 9	HC Wainwright & Co.	Maintains	Buy → Buy	—	$25.90	$26.21	+1.2%	+7.2%	-4.2%	-0.2%	-2.6%	+4.4%
Oct 9	Wedbush	Maintains	Outperform → Outperform	—	$25.90	$26.21	+1.2%	+7.2%	-4.2%	-0.2%	-2.6%	+4.4%
May 16	HC Wainwright & Co.	Maintains	Buy → Buy	—	$9.74	$9.75	+0.1%	+7.5%	+5.2%	+4.3%	-4.7%	+4.7%
Mar 12	HC Wainwright & Co.	Maintains	Buy → Buy	—	$7.25	$7.49	+3.3%	+13.2%	+6.3%	-5.5%	+2.2%	-6.3%
Mar 12	Guggenheim	Maintains	Buy → Buy	—	$7.25	$7.49	+3.3%	+13.2%	+6.3%	-5.5%	+2.2%	-6.3%
Dec 11	Morgan Stanley	Maintains	Overweight → Overweight	—	$9.50	$9.32	-1.9%	-3.6%	+1.0%	-3.6%	-1.7%	+8.1%

Data updated apr 27, 2026 11:32am · Source: massive.com